Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Finished Goods (2022 - 2025)

Historic Finished Goods for InMed Pharmaceuticals (INM) over the last 4 years, with Q3 2025 value amounting to $295809.0.

  • InMed Pharmaceuticals' Finished Goods fell 6809.59% to $295809.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $295809.0, marking a year-over-year decrease of 6809.59%. This contributed to the annual value of $676178.0 for FY2025, which is 1958.04% down from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Finished Goods of $295809.0 as of Q3 2025, which was down 6809.59% from $676178.0 recorded in Q2 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Finished Goods peaked at $927182.0 during Q3 2024, and registered a low of $231956.0 during Q1 2025.
  • Its 4-year average for Finished Goods is $613014.3, with a median of $605956.0 in 2022.
  • Per our database at Business Quant, InMed Pharmaceuticals' Finished Goods soared by 8873.19% in 2023 and then plummeted by 6809.59% in 2025.
  • Quarter analysis of 4 years shows InMed Pharmaceuticals' Finished Goods stood at $605956.0 in 2022, then dropped by 7.94% to $557859.0 in 2023, then rose by 21.03% to $675164.0 in 2024, then tumbled by 56.19% to $295809.0 in 2025.
  • Its Finished Goods stands at $295809.0 for Q3 2025, versus $676178.0 for Q2 2025 and $231956.0 for Q1 2025.